NO993875D0 - Sammensetninger for behandling av ARDS eller IRDS inneholdende 3-(cyklopropylmetoksy)-N-(3,5-diklor-4-pyridinyl)-4-(difluormetoksy)benzamid og lungesurfaktant - Google Patents

Sammensetninger for behandling av ARDS eller IRDS inneholdende 3-(cyklopropylmetoksy)-N-(3,5-diklor-4-pyridinyl)-4-(difluormetoksy)benzamid og lungesurfaktant

Info

Publication number
NO993875D0
NO993875D0 NO993875A NO993875A NO993875D0 NO 993875 D0 NO993875 D0 NO 993875D0 NO 993875 A NO993875 A NO 993875A NO 993875 A NO993875 A NO 993875A NO 993875 D0 NO993875 D0 NO 993875D0
Authority
NO
Norway
Prior art keywords
irds
cyclopropylmethoxy
ards
treatment
difluoromethoxy
Prior art date
Application number
NO993875A
Other languages
English (en)
Other versions
NO993875L (no
NO323594B1 (no
Inventor
Paul-Georg Germann
Ulrich Kilian
Rolf Beume
Hermann Amschler
Uwe Krueger
Dietrich Hofner
Original Assignee
Byk Gulden Lomberg Chem Fab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19705924A external-priority patent/DE19705924A1/de
Application filed by Byk Gulden Lomberg Chem Fab filed Critical Byk Gulden Lomberg Chem Fab
Publication of NO993875D0 publication Critical patent/NO993875D0/no
Publication of NO993875L publication Critical patent/NO993875L/no
Publication of NO323594B1 publication Critical patent/NO323594B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO993875A 1997-02-17 1999-08-11 Sammensetninger for behandling av IRDS eller ARDS omfattende N-(3,5-diklorpyrid-4-yl)-3-cyklopropylmetoksy-4-difluormetoksybenzamid og en lungesurfaktantsammensetning, samt deres anvendelse NO323594B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19705924A DE19705924A1 (de) 1997-02-17 1997-02-17 Neue Zusammensetzungen
EP97102639 1997-02-19
PCT/EP1998/000847 WO1998035683A1 (en) 1997-02-17 1998-02-14 Compositions for the treatment of ards or irds containing 3-(cyclopropylmethoxy)-n-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide and lung surfactant

Publications (3)

Publication Number Publication Date
NO993875D0 true NO993875D0 (no) 1999-08-11
NO993875L NO993875L (no) 1999-08-11
NO323594B1 NO323594B1 (no) 2007-06-11

Family

ID=26033977

Family Applications (1)

Application Number Title Priority Date Filing Date
NO993875A NO323594B1 (no) 1997-02-17 1999-08-11 Sammensetninger for behandling av IRDS eller ARDS omfattende N-(3,5-diklorpyrid-4-yl)-3-cyklopropylmetoksy-4-difluormetoksybenzamid og en lungesurfaktantsammensetning, samt deres anvendelse

Country Status (26)

Country Link
US (2) US6436970B1 (no)
EP (1) EP0977577B1 (no)
JP (1) JP4763104B2 (no)
KR (1) KR100640025B1 (no)
CN (1) CN1123345C (no)
AT (1) ATE336254T1 (no)
AU (1) AU734122B2 (no)
BR (1) BR9807399B1 (no)
CA (1) CA2276429C (no)
CZ (1) CZ293871B6 (no)
DE (1) DE69835594T2 (no)
DK (1) DK0977577T3 (no)
EA (1) EA001758B1 (no)
EE (1) EE04094B1 (no)
ES (1) ES2271990T3 (no)
HK (1) HK1026145A1 (no)
HU (1) HU227520B1 (no)
IL (1) IL130658A (no)
NO (1) NO323594B1 (no)
NZ (1) NZ336569A (no)
PL (1) PL190775B1 (no)
PT (1) PT977577E (no)
SI (1) SI0977577T1 (no)
TR (1) TR199901772T2 (no)
UA (1) UA50808C2 (no)
WO (1) WO1998035683A1 (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100640025B1 (ko) * 1997-02-17 2006-10-31 알타나 파마 아게 3-(시클로프로필메톡시)-ｎ-(3,5-디클로로-4-피리디닐)-4-(디플루오로메톡시)벤즈아미드 및 폐 계면활성제를 포함하는 성인성호흡 곤란 증후군 및 영아 호흡 장애 증후군을 치료하기 위한 조성물
AU6083899A (en) 1999-09-16 2001-04-17 Aventis Behring Gmbh Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
DE19957898A1 (de) * 1999-12-01 2001-06-07 Byk Gulden Lomberg Chem Fab Neue Verwendung von Lungensurfactant
AU2001261962B2 (en) 2000-05-25 2005-04-21 Merck Frosst Canada Ltd Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
DE60205899T2 (de) 2001-05-24 2006-06-29 Merck Frosst Canada & Co, Kirkland 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
US20030099601A1 (en) * 2001-11-27 2003-05-29 Gordon Marc S. Inhalation lung surfactant therapy
AU2002357168A1 (en) * 2001-12-12 2003-07-09 Penn State Research Foundation Surfactant prevention of lung complications from cancer chemotherapy
US20030170223A1 (en) * 2002-02-01 2003-09-11 Board Of Trustees Of Michigan State University Pulmonary vasodilator surfactant compositions and method of use
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
US6822114B1 (en) 2002-10-08 2004-11-23 Albemarle Corporation Process for production of fluoroalkoxy-substituted benzamides and their intermediates
PL214869B1 (pl) * 2002-11-27 2013-09-30 Nycomed Gmbh Synergistyczna kombinacja zawierajaca roflumilast i (R, R)-formoterol
JP2006508994A (ja) * 2002-11-27 2006-03-16 アルタナ　ファルマ　アクチエンゲゼルシャフト ロフルミラスト及びホルモテロールを含有する新規の相乗組合せ
DE602004023921D1 (de) 2003-03-10 2009-12-17 Nycomed Gmbh Neues verfahren zur herstellung vonroflumilast
ES2383206T3 (es) * 2003-06-16 2012-06-19 Nycomed Gmbh Composición que comprende un tensioactivo pulmonar y sildenafilo para el tratamiento de neumopatías
EP1781323B1 (en) * 2004-08-06 2010-02-17 Nycomed GmbH Composition comprising a pulmonary surfactant and a tnf-derived peptide
JP5383183B2 (ja) * 2005-03-16 2014-01-08 タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング ロフルミラストを含有する矯味された剤形
CA2670730A1 (en) * 2006-12-13 2008-06-26 Gilead Sciences, Inc. Monophosphates as mutual prodrugs of anti-inflammatory signal transduction modulators (aistm's) and beta-agonists for the treatment of pulmonary inflammation and bronchoconstriction
WO2009055788A1 (en) * 2007-10-26 2009-04-30 Aeris Therapeutics, Inc. Pneumoreductive therapy and compositions useful therein
EP3027738B1 (en) * 2013-08-01 2022-03-02 Swedish StromaBio AB Mscs in the treatment of inflammatory pulmonary diseases
CN104800214A (zh) * 2014-01-27 2015-07-29 成都英诺新科技有限公司 一种罗氟司特吸入气雾剂复方及制备方法
RU2728821C1 (ru) * 2020-05-13 2020-07-31 Федеральное государственное бюджетное учреждение науки "Научный центр биомедицинских технологий Федерального медико-биологического агентства" (ФГБУН НЦБМТ ФМБА России) Способ лечения острого респираторного дистресс-синдрома даларгином и легочным сурфактантом

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4223040A (en) * 1974-11-26 1980-09-16 Carroll John M Lauric acid for the prevention and treatment of mycobacterial diseases
JPS5795920A (en) * 1980-12-04 1982-06-15 Teijin Ltd Remedy for respiratory disease
JPS5845299A (ja) * 1981-09-10 1983-03-16 東京田辺製薬株式会社 新規な表面活性物質、その製造法及びそれを含有する呼吸窮迫疾候群治療剤
GR82072B (no) * 1983-05-11 1984-12-13 Byk Gulden Lomberg Chem Fab
US4906476A (en) * 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
US5006343A (en) * 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
AU687087B2 (en) * 1993-07-02 1998-02-19 Takeda Gmbh Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
US5856196A (en) * 1993-10-25 1999-01-05 Beth Israel Hospital Processes for quantitating phosphoglycerides in a lipid mixture and diagnostic uses therefor
GB9401460D0 (en) 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
DE4434629C1 (de) * 1994-09-28 1996-06-27 Byk Gulden Lomberg Chem Fab Zusammensetzungen zur Behandlung von IRDS und ARDS
US5531219A (en) * 1994-11-04 1996-07-02 Alliance Pharmaceutical Corp. Use of liquid fluorocarbons to facilitate pulmonary drug delivery
US5698537A (en) * 1996-06-18 1997-12-16 Clarion Pharmaceuticals Inc. Method of lowering the viscosity of mucus
KR100640025B1 (ko) * 1997-02-17 2006-10-31 알타나 파마 아게 3-(시클로프로필메톡시)-ｎ-(3,5-디클로로-4-피리디닐)-4-(디플루오로메톡시)벤즈아미드 및 폐 계면활성제를 포함하는 성인성호흡 곤란 증후군 및 영아 호흡 장애 증후군을 치료하기 위한 조성물
US6180142B1 (en) * 1998-08-21 2001-01-30 The Regents Of The University Of California Reduction of surfactant inactivation in pulmonary surfactant therapy
KR20020048911A (ko) * 1999-06-29 2002-06-24 엘-테크 코포레이션 화학 필름의 세정 및 건조 방법과 그 장치

Also Published As

Publication number Publication date
HU227520B1 (hu) 2011-07-28
CN1248169A (zh) 2000-03-22
PL190775B1 (pl) 2006-01-31
ES2271990T3 (es) 2007-04-16
US20020132835A1 (en) 2002-09-19
NZ336569A (en) 2001-04-27
CZ293871B6 (cs) 2004-08-18
SI0977577T1 (sl) 2007-02-28
HK1026145A1 (en) 2000-12-08
WO1998035683A1 (en) 1998-08-20
US6998410B2 (en) 2006-02-14
DE69835594D1 (de) 2006-09-28
TR199901772T2 (no) 1999-09-21
ATE336254T1 (de) 2006-09-15
CZ291499A3 (cs) 2000-02-16
JP2001512452A (ja) 2001-08-21
CA2276429C (en) 2007-06-19
AU734122B2 (en) 2001-06-07
IL130658A0 (en) 2000-06-01
NO993875L (no) 1999-08-11
JP4763104B2 (ja) 2011-08-31
DK0977577T3 (da) 2006-12-18
EE04094B1 (et) 2003-08-15
PL335134A1 (en) 2000-04-10
AU6497398A (en) 1998-09-08
HUP0001043A3 (en) 2002-12-28
EA001758B1 (ru) 2001-08-27
BR9807399B1 (pt) 2011-04-19
CA2276429A1 (en) 1998-08-20
PT977577E (pt) 2007-02-28
EE9900279A (et) 2000-02-15
EA199900645A1 (ru) 2000-04-24
KR20000071112A (ko) 2000-11-25
EP0977577B1 (en) 2006-08-16
CN1123345C (zh) 2003-10-08
EP0977577A1 (en) 2000-02-09
KR100640025B1 (ko) 2006-10-31
IL130658A (en) 2004-07-25
NO323594B1 (no) 2007-06-11
DE69835594T2 (de) 2007-08-16
US6436970B1 (en) 2002-08-20
HUP0001043A2 (hu) 2000-09-28
UA50808C2 (uk) 2002-11-15
BR9807399A (pt) 2000-03-14

Similar Documents

Publication Publication Date Title
NO993875D0 (no) Sammensetninger for behandling av ARDS eller IRDS inneholdende 3-(cyklopropylmetoksy)-N-(3,5-diklor-4-pyridinyl)-4-(difluormetoksy)benzamid og lungesurfaktant
NO20025355D0 (no) Farmasöytisk preparat som omfatter en faktor VIIa og en faktor XIII
NO2008010I1 (no) Kombinasjon av efavirenz, emtricitabin og tenofovirdisoproks: 1 eller salter derav
DK0705099T3 (da) Anvendelse af modafinil til behandling af søvnapnø og åndedrætslidelser af central oprindelse
DK1363608T3 (da) Formuleringer omfattende ibuprofen og diphenhydramin og deres anvendelse til behandling af sovnforstyrrelser
DK1237549T3 (da) Lipoxin A4 og dets analoger til behandling af törre öjne
DK0494405T3 (da) Anvendelse af thiazolidin-4-carboxylatderivater til behandling af lungesygdomme
ATE169225T1 (de) Anwendung von urodilatin bei lungen- und bronchialerkrankungen
ATE165827T1 (de) Herstellung von n-acetylneuraminsäure-derivaten
ATE514750T1 (de) Polyorganosiloxanzusammensetzung in emulsion und daraus hergestellte kosmetische formulierung
EP1403432A4 (en) PAPER FOR SMOKING ARTICLES REDUCING VISIBLE LATERAL SMOKE QUANTITY
DK0764023T3 (da) Forbindelser og præparater til administrering via oral inhalation eller insufflation
BE870934Q (fr) Dispositif d'agrafage et agrafe, notamment pour cadres de bois
DK210081A (da) 1-(3,5-bistrifluormethylphenyl)-3-(4-tert. butylpiperidino)-prop-1-yn eller syreadditionssalte deraf dets fremstilling og anvendelse som rodenticid
DK303789D0 (da) Proteinet curuculin og dets anvendelse som smagsmodifaktor
DK284588A (da) Beta-lactam-forbindelser, deres fremstilling og anvendelse som laegemidler.
ATE311891T1 (de) Cytidin-diphosphocholin gegen diabetische neuropathie
HUP0003463A2 (hu) Piperidinil-metil-oxazolidinon-származék, eljárás ennek előállítására és a vegyületet tartalmazó gyógyszerkészítmény
NO911465D0 (no) Fremgangsmaate for fremstilling av 4-(3-(4-oksotiazoldinyl))-butynylaminer og deres anvendelse som medikamenter.
DK74184A (da) Anti-angina-middel
NO20000262D0 (no) Plasmider, deres konstruksjon og deres anvendelse i fremstilling av interleukin-4 og interleukin-4-muteiner
DE69129083D1 (de) Therapeutisches Mittel zur Vorbeugung und Behandlung des Atemnotsyndroms bei Erwachsenen
DE60318423D1 (de) Behandlung des typ 1 diabetes vor und nach expression von prädispositionsmarkern
ES2188189T3 (es) Composiciones que comprenden derivados de acido fenil-amino-tiofeno-acetico para el tratamiento del sindrome de angustia respiratoria aguda o de adultos (ards) y del sindrome de angustia respiratoria de niños (irds).
SE9403861D0 (sv) Novel medicinal use

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: TAKEDA GMBH, DE

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: TAKEDA GMBH, DE

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ASTRAZENECA AB, SE

MM1K Lapsed by not paying the annual fees